Results 81 to 90 of about 25,780 (241)

Scaling temporal resolution from mice to humans: Challenges and innovations in preclinical imaging of translational models

The Journal of Physiology, EarlyView.
Abstract figure legend Temporal scaling physiology differs significantly between mice and humans. Mice have higher metabolism, heart and respiratory rate, as well as faster blood flow rates, brain activity and physiological dynamics over time. These differences influence the temporal resolution needed in preclinical imaging of mouse models to ...
Sara Gargiulo, Matteo Gramanzini
wiley   +1 more source

Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases

Case Reports in Oncology, 2014
Introduction: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease.
Donato Callegaro-Filho, John J. Kavanagh, Alpa M. Nick, Pedro T. Ramirez, Kathleen M. Schmeler   +4 more
doaj   +1 more source

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet Oncology, 2018
BACKGROUND Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum ...
R. Chekerov, F. Hilpert, S. Mahner, A. El-Balat, P. Harter, N. de Gregorio, C. Fridrich, S. Markmann, J. Potenberg, R. Lorenz, G. Oskay-Oezcelik, Marcus Schmidt, P. Krabisch, H. Lueck, R. Richter, E. Braicu, A. du Bois, J. Sehouli, W. Lichtenegger, Isil Yalcinkaya, Marion Kittner, Ellen Konwert, Maren Keller, A. Mustea, D. Koensgen-Mustea, K. Pietzner, Oumar Camara, P. Wimberger, G. Elser, Sandra Polleis   +29 more
semanticscholar   +1 more source

Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
ABSTRACT Background Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened ...
Sudarshawn Damodharan, Mariah Wright‐Nadkarni, Mohamed S. Abdelbaki, Girish Dhall   +3 more
wiley   +1 more source

Organoids in pediatric cancer research

FEBS Letters, Volume 600, Issue 21, Page 3221-3240, November 2026.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Image‐guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF‐labelled lipids and topotecan to visualise the effects of hyperthermia in tumours

Journal of Controlled Release, 2018
Image guided drug delivery using imageable thermosensitive liposomes (iTSLs) and high intensity focused ultrasound (FUS or HIFU) has attracted interest as a novel and non‐invasive route to targeted delivery of anti‐cancer therapeutics.
M. Centelles, Michael Wright, Po-Wah So, Maral Amrahli, Xiao-Yan Xu, J. Stebbing, Andrew D. Miller, W. Gedroyc, M. Thanou   +8 more
semanticscholar   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, Volume 38, Issue 61, 2 November 2026.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Ovarian Carcinoma: Signal Pathways and Clinical Studies

MedComm, Volume 7, Issue 11, November 2026.
This review synthesizes current knowledge on the pathophysiological mechanisms driven by the Notch, HER2, DNA damage repair (DDR), PI3K/AKT/mTOR, and angiogenesis (VEGF) pathways in ovarian cancer. A key focus is placed on summarizing subsequent targeted therapeutic strategies, detailing the landscape of associated clinical trials and their ...
Yanru Long, Houhui Shi, Jiatian Ye, Xiaorong Qi   +3 more
wiley   +1 more source

Nanoprobe‐Enabled Precision Imaging and Panoramic Boundary Delineation in Retinoblastoma

Cancer Innovation, Volume 5, Issue 5, October 2026.
This review highlights that nanoprobe‐enabled multimodal imaging, combined with targeted probe design and AI‐assisted analysis, significantly enhances the precise visualization and boundary delineation of retinoblastoma. It further outlines key challenges and directions for translating high‐performance imaging nanoprobes into clinical practice.
Xuefei He, Precious Amarachi Ikwuagwu, Wenjing Pang, Aomen Chen, Lingchao Xiang, Feng Chen, Chen Xu, Aiguo Wu   +7 more
wiley   +1 more source

Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan

International Journal of Molecular Sciences, 2019
Epithelial ovarian cancer (EOC) is one of the deadliest gynecological malignancies. Topotecan remains an essential tool in second-line therapy; even so, most patients develop resistance within a short period of time.
O. Menyhárt, J. Fekete, Balázs Győrffy   +2 more
semanticscholar   +1 more source